This addition to the framework agreement (“Addendum”) is established on August 27, 2019 and sets out the terms of the agreements reached by the parties with respect to the OviTex LPR Low Profile Robotic Product (“LPR product”). This framework agreement (hereafter referred to as the “agreement” or “Umbrella agreement”) is intended for the joint research and development of robotic and space technologies including the demonstration of algorithms, concepts and prototypes integrated into autonomous systems and robotics. The agreement establishes an intermediate framework between the parties. This schedule is intended to conduct standard testing and evaluation of materials and components in accordance with NASA-STD-6001 Inflammability, off-gas gasing, compatibility requirements and testing methods. As part of this agreement, approximately 150 standard test requirements will be executed. The WSTF team For standard testing and oxygen analysis, it has been analyzing space vehicle safety materials for more than 30 years and offers unique expertise in the interpretation of themes and data, custom special equipment required for testing and data acceptance qualification. These test services are not commercially available in the United States and WSTF is clearly qualified for the performance of these services. The test is conducted in accordance with B/E Aerospace`s protocol.b.a. Collins Aerospace, a unit of united Technologies Corporation (“Collins”). The objective of this schedule is NASA`s JSC/WSTF for the preparation of facilities, inspections and functional testing of up to five R40b engines. Inspections and tests are conducted both before and after hot fire tests (hot fire tests to be conducted under a separate agreement). After post-burn inspection and functional control, up to five (5) R40b nozzles are delivered to Boeing. This addition to the second amended and revised Framework Licensing, Product Development and Procurement Agreement (this “addendum”) is established on February 15, 2020 by and between TELA Bio, Inc.
(“TELA Bio”) and Aroa Biosurgery Limited (“Aroa”) and defines the terms of TELA Bio and Aroa`s divestment agreements. Transfer and transport of Aroa to FDA TelA Bio 510 (k) Clearances (K183398) for endoform® Restella`s reconstructive model (the “Restella product”), as described in Figure B (the “restella product clearance”).